Sponsors / ACRS
ACRS

Aclaris Therapeutics, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
8Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)NCT04524858ACRSPhase 2Terminated2021-02-25Actual
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisNCT04598269ACRSPhase 2Completed2021-04-08Actual
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05216224ACRSPhase 2Completed2022-12-23Actual
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)NCT05279417ACRSPhase 2Completed2023-09-05Actual
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisNCT05432596ACRSPhase 2Completed2023-10-26Actual
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisNCT05511519ACRSPhase 2Terminated2023-12-06Actual
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisNCT06585202ACRSPhase 2Completed2025-03-13Actual
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706ACRSPhase 2Active not recruiting2026-08Estimated

Latest recorded trial changes

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417 · Aclaris Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Proportion of patients achieving ACR20 at Week 12; timeFrame: Baseline to Week 12

+ Updated value

measure: Percentage of Participants Achieving ACR20 at Week 12; description: Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP. Model-based estimates and 95% confidence intervals (CIs) were produced.; timeFrame: Week 12

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05216224 · Aclaris Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.

+ Updated value

measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12

Check registry source · The saved outcome text may be shortened. Check the source for full wording.